Meeting
2014 ASCO Annual Meeting
A phase 1 study of the c-Met inhibitor tivantinib (ARQ 197, IND#112603) in children with relapsed or refractory solid tumors: A Children’s Oncology Group study.
Authors
James I. Geller
Cincinnati Children's Hospital Medical Center, Cincinnati, OH
James I. Geller , John Peter Perentesis , Charlotte H. Ahern , Rachel A. Kudgus , Elizabeth Fox , Susan Blaney , Brenda Weigel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Signal Transduction
Clinical Trial Registration Number
NCT01725191
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 2627)
DOI
10.1200/jco.2014.32.15_suppl.2627
Abstract #
2627
Poster Bd #
90
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A Children's Oncology Group Phase I Consortium Study.
First Author: T. R. Hummel
Poster
2015 ASCO Annual Meeting
Phase I trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A Children’s Oncology Group Study.
First Author: Robin Elizabeth Norris
Poster
2013 ASCO Annual Meeting
A phase I trial and pharmacokinetic study of trebananib (AMG386) in children with recurrent or refractory solid tumors: A Children’s Oncology Group Phase 1 Consortium report.
First Author: Sarah Leary
Poster
2016 ASCO Annual Meeting
A phase 1 study of eribulin mesylate (E7389), a novel microtubule targeting chemotherapeutic agent in children with refractory or recurrent solid tumors (excluding CNS), including lymphomas: a Children’s Oncology Group Phase 1 Consortium study (ADVL1314).
First Author: Eric Schafer